Burning Rock Biotech (BNR) EBT (2019 - 2026)

Burning Rock Biotech (BNR) has reported EBT for 8 consecutive years, with -$2.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, EBT fell 36.43% year-over-year to -$2.5 million; the TTM figure through Mar 2026 stood at -$8.2 million (up 74.44% YoY), while the FY2025 annual figure was -$7.7 million, up 83.52% from the prior year.
• EBT came in at -$2.5 million for Q1 2026 at Burning Rock Biotech, down from -$2.1 million in the prior quarter.
• The five-year high for EBT was -$1.3 million in Q2 2025, with the low at -$41.2 million in Q1 2022.
• Average EBT over 5 years is -$17.2 million, with a median of -$16.8 million recorded in 2024.
• Across the five-year window, EBT tumbled 57.61% in 2022 and jumped 91.11% in 2025, its largest moves.
• Year by year, EBT stood at -$31.1 million in 2022, then advanced by 26.96% to -$22.7 million in 2023, then jumped by 54.14% to -$10.4 million in 2024, then surged by 80.07% to -$2.1 million in 2025, then retreated by 20.44% to -$2.5 million in 2026.
• According to Business Quant data, EBT over the past three periods registered -$2.5 million, -$2.1 million, and -$2.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.